CAVI-Lowering Effect of Pitavastatin May Be Involved in the Prevention of Cardiovascular Disease: Subgroup Analysis of the TOHO-LIP-Reference-Cited by-同舟云学术

CAVI-Lowering Effect of Pitavastatin May Be Involved in the Prevention of Cardiovascular Disease: Subgroup Analysis of the TOHO-LIP

Published:2021-10-01 Issue:10 Volume:28 Page:1083-1094
ISSN:1340-3478
Container-title:Journal of Atherosclerosis and Thrombosis
language:en
Short-container-title:JAT

Author:

Saiki Atsuhito¹,Watanabe Yasuhiro¹,Yamaguchi Takashi¹,Ohira Masahiro¹,Nagayama Daiji¹,Sato Naoko²,Kanayama Mizuho²,Takahashi Mao³,Shimizu Kazuhiro³,Moroi Masao⁴,Miyashita Yoh⁵,Shirai Kohji⁶,Tatsuno Ichiro¹

Affiliation:

1. Center of Diabetes, Endocrine and Metabolism, Toho University Sakura Medical Center

2. Pharmaceutical Unit, Toho University Sakura Medical Center

3. Division of Cardiovascular Medicine (Sakura), Department of Internal Medicine, Faculty of Medicine, Toho University

4. Division of Cardiovascular Medicine (Ohashi), Department of Internal Medicine, Faculty of Medicine, Toho University

5. Medical Correction Center in East Japan

6. Department of Internal Medicine, Mihama Hospital

Publisher

Japan Atherosclerosis Society

Subject

Biochemistry (medical),Cardiology and Cardiovascular Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/jat/28/10/28_60343/_pdf

Reference32 articles.

1. 1) Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994; 344: 1383-1389

2. 2) Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med, 1995; 333: 1301-1307

3. 3) Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH; CARDS investigators: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 2004; 364: 685-696

4. 4) Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J; ASCOT investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 2003; 361: 1149-1158

5. 5) LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart J-C, Gotto AM, Greten H, Kastelein JJP, Shepherd J, Wenger NK, for the Treating to New Targets (TNT) Investigators: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med, 2005; 352: 1425-1435

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Indicator of Arterial Stiffness START—Is There a Prognostic Value of Its Dynamics in Patients with Coronary Artery Disease?;Biomedicines;2024-07-23

2. Identifying the high-benefit population for weight management-based cardiovascular disease prevention in Japan;Preventive Medicine Reports;2024-07

3. Prognostic Value of Cardio-Ankle Vascular Index for Cardiovascular and Kidney Outcomes;JACC: Advances;2024-07

4. Dynamics of the State of Arterial Stiffness as a Possible Pathophysiological Factor of Unfavorable Long-Term Prognosis in Patients after Coronary Artery Bypass Grafting;Biomedicines;2024-05-06

5. Increased Cardio-ankle Vascular Index Values in Migraine Patients With Aura;Angiology;2024-01-18